Clinical Trial Update: The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating the efficacy and safety of a drug named 626 for systemic lupus erythematosus. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• 626

Snippet

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Conditions: Systemic Lupus Erythematosus (SLE) | Phase 1, Phase 2 | Status: RECRUITING